Vitamin K Deficiency Linked to Increased Risk of CVD in New Study

Arteriosclerosis, Thrombosis, and Vascular Biology, the journal for the American Heart Association, just published an 11-year study that draws a clear line between vitamin K deficiency and an increased risk of coronary heart disease.

To date, 19 Vitamin K–dependent proteins (VKDPs) have been described, with important roles in coagulation, platelet function, and vascular biology. Produced in an inactive form, all VKDPs obtain biological activity through the conversion of a glutamic acid residue into glutamate, a complex process requiring vitamin K.

“Western populations are not afflicted with blood diseases because of a vitamin K1 deficiency. Clearly we get enough vitamin K in our diets to effectively coagulate blood; however, our total K status outside the liver – particularly Vitamin K2 status – plays an important role in maintaining and supporting our heart and bone health,” says Dr. Hogne Vik, chief medical officer with NattoPharma, world leader in vitamin K2 research and development and exclusive global supplier of MenaQ7® Vitamin K2 as MK-7.

The authors investigated whether VKDP activity was associated with cardiovascular disease in a random sample of 709 multi-ethnic adults free of cardiovascular disease drawn from the Multi-Ethnic Study of Atherosclerosis (MESA), who were followed up with for 11 years. The circulating des-γ-carboxy prothrombin (DCP) concentrations were measured to indicate lower VKDP activity. [Note: des-γ-carboxy prothrombin (DCP) is also known as protein induced by vitamin K absence/antagonist-II (PIVKA-II).]

The results showed that ischemic cardiovascular disease incidence rates were higher with greater concentration of DCP. Further, that subjects with the lowest activity of VKDP revealed two-times higher risk of cardiovascular events than people with the highest activity of VKDP.

“The study showed that a total of 84% of the cohort participants had a DCP >2 ng/mL (considered the threshold for VKDP inactivity), so the majority of participants were vitamin K subdeficient. Moreover, it has been shown that participants with higher DCP concentrations (i.e., lower VKDP activity) tended to be older,” continues Dr. Vik, adding that a similar finding was shown by E. Theuwissen et al. (2014)1: that adults above 40 years showed the largest tissue-specific vitamin deficiency after children.

Further, there are other studies where VKDP correlates with cardiovascular survival risk:

  • Schlieper et al. 20112 showed that      lower levels of circulating dp-cMGP may serve a s predictor of mortality      in dialysis patients.
  • Mayer      et al. 20163 concluded that concomitant abnormality of      uncarboxylated MGP leads to about a two-fold increase of the relative      mortality risk in chronic patients      with vascular disease.
  • Liu      et al. 20154 showed that higher dp-ucMGP predicts total      non-cancer and cardiovascular mortality, but lower coronary risk.

“Researchers have identified populations that consume large amounts of Vitamins K1 and K2 have better heart

and bone health outcomes. Intervention studies have also demonstrated that adding vitamin K reduces cardiovascular risk factors,” concludes Dr. Vik. “This is yet another important study showing that a lack of K vitamins, particularly vitamin K2, results in increased cardiovascular risk. This finding should raise awareness of this important class of proteins as a potential contributor to cardiovascular disease protection.”

To review the study, visit http://atvb.ahajournals.org/content/early/2016/03/31/ATVBAHA.116.307273.abstract.

References:

1 Theuwissen et al. Vitamin K status in healthy volunteers. Food & Function. 2014;5(2):229-34.

2 Schlieper et al. Circulating Nonphosphorylated Carboxylated Matrix Gla Protein Predicts Survival in ESRD . J Am Soc Nephrol 2011; 22: 387–395.

3 Mayer et al. The abnormal status of uncarboxylated matrix Gla protein species represents an additional mortality risk in heart failure patients with vascular disease. International Journal of Cardiology 203 (2016) 916–922.

4 Liu YP et al. Inactive matrix Gla protein is causally related to adverse health outcomes: a Mendelian randomization study in a Flemish population. Hypertension. 2015 Feb;65(2):463-70.

For more information, please contact:

Kate Quackenbush, Director of Communications

NattoPharma USA, Inc.

Phone: 609-643-0749

E-mail: kate.quackenbush@nattopharma.com


About MenaQ7®

MenaQ7® is the best documented, commercially available vitamin K2 as MK-7 with guaranteed actives and stability, clinical substantiation, and international patents granted and pending. MenaQ7® is available in two varieties: natural vitamin K2 as MK-7 Crystals and nature-identical synthetic vitamin K2 as MK-7 PURE. For more information on the health benefits of MenaQ7, visit menaq7.com.

About NattoPharma

NattoPharma ASA, based in Norway, is the  world’s leader in vitamin K2 research and development. NattoPharma is the exclusive international supplier of MenaQ7® Vitamin K2 as MK-7, and has a multi-year research and development program to substantiate and discover the health benefits of vitamin K2 for applications in the marketplace for functional food and dietary supplements. With a global presence, the company established its North American subsidiary, NattoPahrma USA, Inc., in Meuchen, NJ. For more information, visit nattopharma.com.

Tags:

About Us

NattoPharma, the world leader in Vitamin K2 Research and Development, has invested millions of dollars in in-vitro, in-vivo, and clinical studies to document the effects of MenaQ7® Vitamin K2 as MK-7. This commitment has created the only patented and clinically validated K2 on the market. After establishing the first commercial Vitamin K2 with its flagship brand, MenaQ7®, NattoPharma has consistently answered and met market needs through the development of new production technologies:• In 2012, the company introduced MenaQ7® Crystals, which represented an important breakthrough in the new generation of Vitamin K2 products, producing the purest natural MK-7 available.• In 2014, NattoPharma introduced the only all-trans nature-identical synthesized Vitamin K2, MenaQ7® PURE. Not only did the company succeed in changing the market with MenaQ7® PURE – offering a high-quality, competitively priced ingredient – but its efforts were rewarded with the NutrAward for Best Functional Ingredient at Natural Products West/engredea 2015. Vitamin K2 is essential for the body to utilize calcium to build healthy, strong bones and to inhibit calcium deposits in the arteries. Published clinical studies have demonstrated the high bioavailability and proof of efficacy for Nattopharma’s all-trans MK-7 products in healthy and diseased populations, for bone and cardiovascular health. NattoPharma continues to build its competitive advantage through focuson IPR and has patents both granted and pending related to relevant healthbenefits and market segments, creating extra value for its customers. And NattoPharma staff consists of professionals people with longstanding experience in medical and biochemical research as well as pharmaceutical and food supplement development. By understanding and controlling the chemistry, NattoPharma provides the market all-trans MK-7 products, while our sales and marketing team has extensive knowledge of international market demands with which it supports our partners.